Loading...
XNASQURE
Market cap849mUSD
Dec 23, Last price  
17.43USD
1D
2.65%
1Q
239.11%
Jan 2017
211.25%
IPO
29.98%
Name

Uniqure NV

Chart & Performance

D1W1MN
XNAS:QURE chart
P/E
—
P/S
53.63
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
5.99%
Rev. gr., 5y
7.02%
Revenues
16m
-85.12%
004,063,9065,697,01810,304,37525,098,00013,107,00011,284,0007,281,00037,514,000524,002,000106,483,00015,843,000
Net income
-308m
L+143.30%
00000-73,374,000-80,389,000-83,304,000-128,011,000-125,024,000329,589,000-126,789,000-308,478,000
CFO
-146m
L+0.60%
000018,776,375-72,189,000-64,270,000-76,037,000-98,684,000-134,828,000287,959,000-145,060,000-145,929,000
Earnings
Feb 24, 2025

Profile

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
URL
http://www.uniqure.com/
IPO date
Feb 05, 2014
Employees
501
Domiciled in
NL
Incorporated in
NL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
15,843
-85.12%
106,483
-79.68%
524,002
1,296.82%
Cost of revenue
228,492
200,934
168,524
Unusual Expense (Income)
NOPBT
(212,649)
(94,451)
355,478
NOPBT Margin
67.84%
Operating Taxes
1,921
(1,470)
3,217
Tax Rate
0.90%
NOPAT
(214,570)
(92,981)
352,261
Net income
(308,478)
143.30%
(126,789)
-138.47%
329,589
-363.62%
Dividends
Dividend yield
Proceeds from repurchase of equity
308
1,445
30,899
BB yield
-0.10%
-0.14%
-3.18%
Debt
Debt current
16,688
8,382
5,774
Long-term debt
166,725
174,611
164,711
Deferred revenue
Other long-term liabilities
412,736
10,269
33,778
Net debt
(434,479)
(209,834)
(385,771)
Cash flow
Cash from operating activities
(145,929)
(145,060)
287,959
CAPEX
(7,154)
(17,688)
(17,438)
Cash from investing activities
(205,686)
(182,734)
(67,387)
Cash from financing activities
362,721
1,445
94,858
FCF
(162,072)
(110,744)
300,603
Balance
Cash
617,892
352,843
556,256
Long term investments
39,984
Excess cash
617,100
387,503
530,056
Stockholders' equity
(941,079)
(637,384)
(481,196)
Invested Capital
1,708,238
1,266,554
1,246,474
ROIC
30.14%
ROCE
45.68%
EV
Common stock shares outstanding
47,671
46,735
46,841
Price
6.77
-70.14%
22.67
9.31%
20.74
-42.60%
Market cap
322,733
-69.54%
1,059,483
9.06%
971,482
-39.53%
EV
(111,746)
849,649
585,711
EBITDA
(200,749)
(85,914)
362,777
EV/EBITDA
0.56
1.61
Interest
41,557
11,704
7,474
Interest/NOPBT
2.10%